Enliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two upcoming investor conferences. The company's management will present at the TD Cowen Annual Oncology Innovation Summit on May 27th and the Jefferies Global Healthcare Conference on June 4th, both featuring fireside chats. Webcasts of these events will be available on Enliven's investor relations website.
Biopharma Enliven joins TD Cowen, Jefferies investor chats online
Enliven Therapeutics (Nasdaq: ELVN) announced its participation in two upcoming investor conferences: the TD Cowen Annual Oncology Innovation Summit on May 27 and the Jefferies Global Healthcare Conference on June 4. Management will engage in fireside chats at both events, which will be webcast live and archived on the company's investor relations website. The clinical-stage biopharmaceutical company focuses on developing small molecule therapeutics.
Enliven Therapeutics CMO sells $198,971 in stock
Helen Louise Collins, CMO at Enliven Therapeutics (NASDAQ:ELVN), sold 5,000 shares of company stock for $198,971 after exercising stock options. Following these transactions, Ms. Collins directly holds 25,000 shares and 126,268 derivative securities. This comes amidst positive news for Enliven, including updated data from its ENABLE trial and favorable analyst coverage from Guggenheim, H.C. Wainwright, and Clear Street.
Enliven Therapeutics (ELVN) CMO trades 5,000 shares and exercises 5,000 options
Enliven Therapeutics (ELVN) Chief Medical Officer, Helen Louise Collins, sold 5,000 shares of common stock at various prices between $39.5340 and $41.2052 per share on May 18, 2026. On the same day, she exercised a stock option to acquire 5,000 shares at an exercise price of $2.4800 per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted in October 2025, leaving her with 25,000 directly owned shares and 126,268 exercisable stock options.
Enliven Therapeutics (NASDAQ: ELVN) proposed 15,000-share sale via Jefferies
Enliven Therapeutics (NASDAQ: ELVN) has proposed the sale of 15,000 common shares through Jefferies LLC, as detailed in a Form 144 SEC filing. The filing indicates these shares are related to stock options granted on August 9, 2022, and also outlines several completed dispositions by Helen Collins between February and April 2026, totaling over 130,000 shares with significant proceeds. This notice is a regulatory requirement for planned large sales, ensuring transparency for investors.
Fairmount files 13G/A: 1.86M shares (3.1%) in Enliven Therapeutics (ELVN)
Fairmount Funds Management LLC has filed an amended Schedule 13G/A, disclosing beneficial ownership of 1,855,644 shares, or 3.1%, of Enliven Therapeutics, Inc. (ELVN) common stock. The filing indicates that Fairmount Healthcare Fund II L.P. has delegated sole voting and dispositive power to Fairmount, and its managers Peter Harwin and Tomas Kiselak disclaim beneficial ownership except for reporting obligations. This regulatory update provides transparency on significant institutional holdings and their reported intent.
Polar Capital (ELVN) discloses 5.06M shares; 8.46% ownership reported
Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund have jointly reported a beneficial ownership of 5,056,807 shares of Enliven Therapeutics (ELVN) common stock. This stake represents 8.46% of the class, based on 60,904,946 shares outstanding as of May 7, 2026. The filing, a Schedule 13G/A amendment, indicates sole voting and dispositive power over these shares, signifying a passive investment rather than an intent to influence control.
Commodore holds 4.8M shares in Enliven (NASDAQ: ELVN) after amendment
Commodore Capital and its related entities have reported beneficial ownership of 4,800,940 shares of Enliven Therapeutics (NASDAQ: ELVN) as of March 31, 2026. This stake, representing 7.7% of the company's outstanding shares, includes both issued shares and shares issuable through a pre-funded warrant, subject to a 9.99% beneficial ownership limitation. The filing of this Schedule 13G/A amendment indicates a significant passive investment by Commodore in Enliven Therapeutics.
Polar Capital (ELVN) discloses 5.07M shares, 8.47% stake in ENLIVEN
Polar Capital group has reported an 8.47% stake in Enliven Therapeutics, Inc. (ELVN), comprising 5,065,933 shares of common stock. This disclosure was made via an amended Schedule 13G/A filing, indicating a passive institutional investment. Nicholas Farren, Chief Operating Officer, signed the amendment on behalf of Polar Capital Holdings Plc, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund.
Enliven Therapeutics Insiders Sell US$644k Of Stock, Possibly Signalling Caution
Enliven Therapeutics' insiders have sold US$644k worth of stock over the last year, with no purchases. This selling could be a cautious signal, especially considering the average selling price was US$12.38, which is above the current share price of US$10.35. While insider selling doesn't always indicate future price drops, it's a factor investors might consider.
A Look At Enliven Therapeutics (ELVN) Valuation After Analyst Support And Phase 3 Trial Plans
Enliven Therapeutics (ELVN) is under renewed scrutiny after positive analyst ratings following its Q1 update and plans for Phase 3 trials for ELVN-001. The company's stock has seen significant year-to-date gains but has pulled back recently. While analysts see upside, Enliven's current Price-to-Book ratio of 5.5x is in line with its peer group but significantly higher than the broader US Pharmaceuticals industry, reflecting investor confidence in its pipeline despite its lack of revenue and ongoing losses.
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics announced that additional positive data from its Phase 1 ENABLE clinical trial for ELVN-001 in chronic myeloid leukemia (CML) will be presented at the EHA 2026 Congress. The abstract highlights robust anti-CML activity in heavily pretreated patients, a favorable safety profile, and strong major molecular response rates, including in those previously treated with asciminib. These results reinforce ELVN-001's potential as a best-in-class ATP-competitive inhibitor for CML patients.
Guggenheim Initiates Coverage on Enliven Therapeutics With Buy, $80 Price Target
Guggenheim has initiated coverage on Enliven Therapeutics (ELVN) with a "Buy" rating and a price target of $80. This positive analyst coverage follows several recent company announcements, including Q1 2026 earnings results and positive Phase 1b data for its CML drug, ELVN-001. Enliven Therapeutics focuses on developing small molecule inhibitors for cancer treatment, with lead candidates ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 inhibition.
Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Enliven Therapeutics (ELVN) has announced updates to its board of directors as it prepares for its next phase of development. The article highlights recent analyst ratings for ELVN and lists related SEC filings and insider trading activity, underscoring the company's recent corporate and financial news. This information is sourced from Quantisnow, a real-time market data platform.
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026?
Enliven Therapeutics (ELVN) is highlighted as one of the top-performing healthcare stocks in 2026 due to strong analyst ratings and positive updates regarding its drug pipeline. Mizuho reaffirmed an Outperform rating with a $45 price target, while Clear Street raised its price target to $55, both based on promising developments for ELVN-001. The company also reported a robust financial position with a cash runway extending into the first half of 2029.
5 Best Performing Healthcare Stocks So Far in 2026
This article identifies Enliven Therapeutics, Inc. (NASDAQ: ELVN) as one of the top-performing healthcare stocks in 2026, with a year-to-date share price gain of 167.5%. The company received reaffirmed Outperform and Buy ratings from Mizuho and Clear Street respectively, with increased price targets due to positive clinical trial outlooks for its products. Enliven Therapeutics is a clinical-stage biopharmaceutical company with a strong cash balance expected to fund operations into 2029.
Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $59
Goldman Sachs has reiterated its Buy rating on Enliven Therapeutics (ELVN.US) and increased the target price to $59. This positive adjustment by a major investment bank suggests a strong endorsement of the company's prospects and potential for growth.
JonesTrading Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $45
JonesTrading has initiated coverage of Enliven Therapeutics (ELVN.US) with a Buy rating. The firm has also set a price target of $45 for the company's shares. This signals a positive outlook on Enliven Therapeutics' stock from JonesTrading.
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics reported its first-quarter 2026 financial results, highlighting a strong cash position of $452.4 million, providing a runway into the first half of 2029. The company is advancing its ELVN-001 program for chronic myeloid leukemia (CML), with an expected Phase 1 data update mid-2026 and initiation of the Phase 3 ENABLE-2 pivotal trial in the second half of 2026. Enliven believes ELVN-001 has the potential to be a best-in-class ATP-competitive inhibitor for CML across all lines of therapy.
Enliven Therapeutics (NASDAQ: ELVN) narrows loss and targets Phase 3 trial
Enliven Therapeutics reported a narrower net loss of $23.6 million in Q1 2026, down from $28.5 million a year prior, primarily due to decreased R&D expenses. The company maintained a strong cash position of $452.4 million, which is projected to fund operations into the first half of 2029. Enliven is advancing its chronic myeloid leukemia candidate, ELVN-001, with additional Phase 1 data expected mid-2026 and plans to initiate the pivotal Phase 3 ENABLE-2 trial in the second half of 2026.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Enliven Therapeutics, Inc. (NASDAQ:ELVN) has received a "Moderate Buy" consensus recommendation from six brokerages, with an average 12-month price target of $43.40. While some analysts have raised price targets, others maintain sell ratings. The company recently missed quarterly EPS estimates and has seen insider selling, though institutional investors hold a significant portion of the stock.
Pictet Asset Management Holding SA Sells 94,852 Shares of Enliven Therapeutics, Inc. $ELVN
Pictet Asset Management Holding SA has reduced its stake in Enliven Therapeutics (NASDAQ:ELVN) by 6.8% during the fourth quarter, selling 94,852 shares and now holding 1,303,235 shares valued at $20.07 million. Despite this, other hedge funds increased their positions. Enliven Therapeutics, a clinical-stage biotech company, missed its recent quarterly EPS estimates and analysts currently give the stock a "Moderate Buy" rating with a consensus price target of $43.40.
Director sale notice — Enliven Therapeutics (NASDAQ: ELVN) files Form 144
Enliven Therapeutics director Joseph Lyssikatos has filed a Form 144, indicating proposed sales of 25,000 shares of common stock through Jefferies LLC. The filing also details past dispositions totaling 130,000 shares between February and March 2026, with specific proceeds listed for each transaction. This regulatory notice concerns routine resale activity by an insider, providing transparency regarding personal stock sales.
Enliven Therapeutics (ELVN) price target increased by 11.14% to 52.02
This article reports that the price target for Enliven Therapeutics (ELVN) has been increased by 11.14%. The new price target is set at $52.02.
Enliven Therapeutics (ELVN) price target increased by 11.14% to 52.02
This article reports that the price target for Enliven Therapeutics (ELVN) has been increased by 11.14%, reaching $52.02. This adjustment suggests a positive outlook from analysts for the company's stock performance.
[ARS] Enliven Therapeutics, Inc. SEC Filing
This article announces an ARS SEC Filing by Enliven Therapeutics, Inc. (ELVN) with a neutral sentiment and low impact. The filing was accepted on April 27, 2026, at 4:10 PM. The document directs users to view the PDF and original filing on SEC EDGAR for further details.
We're Not Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn
Enliven Therapeutics has seen its share price rise significantly despite losing money. The company had a cash runway of 6.6 years as of December 2025, with US$463m in cash and a cash burn of US$70m. Analysts are not worried about its cash burn, as it is manageable relative to its market capitalization and has shown a slight reduction.
Enliven Therapeutics (NASDAQ: ELVN) seeks larger share authorization
Enliven Therapeutics (NASDAQ: ELVN) is requesting shareholder approval to increase its authorized common stock from 100 million to 200 million shares to ensure sufficient capacity for future issuances. This proposal is part of five items on the agenda for the company's virtual 2026 annual meeting on June 9, 2026, which also include director elections, auditor ratification, and advisory votes on executive compensation. As of April 10, 2026, there were approximately 60.9 million common shares outstanding.
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Enliven Therapeutics (NASDAQ:ELVN) stock rating from "sell" to "hold," though the broader analyst consensus remains a "Moderate Buy" with a target price of $43.40. This upgrade comes as the company's shares are trading around $44.25, with a market capitalization of $2.69 billion, despite reporting a quarterly EPS loss that missed estimates. Several other firms have also adjusted their price targets for ELVN, with some raising them to as high as $56.00.
Enliven Therapeutics CMO Helen Collins sells over $238k in stock
Helen Collins, CMO of Enliven Therapeutics (NASDAQ:ELVN), sold 4,900 shares of company stock for over $238,000 as part of a Rule 10b5-1 trading plan. This transaction occurred after she exercised stock options and near the company's 52-week high, with analysts maintaining a strong buy rating despite indications of potential overvaluation. The sale coincides with recent positive analyst reports for Enliven following Merck's acquisition of Terns Pharmaceuticals, highlighting the significant market potential in oncology therapies.
Enliven Therapeutics CMO Helen Collins sells over $238k in stock
Helen Collins, CMO of Enliven Therapeutics (NASDAQ:ELVN), sold 4,900 shares for over $238,000 as part of a Rule 10b5-1 plan, having previously acquired shares through options. Following the sale, she still holds significant company stock and derivative securities. Analysts maintain a "strong buy" consensus for Enliven, with recent price target increases driven by market interest in chronic myeloid leukemia therapies, highlighted by Merck's acquisition of Terns Pharmaceuticals.
Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics (ELVN), exercised stock options to acquire 5,000 shares and subsequently sold the same number of shares on April 17, 2026. These transactions, executed under a pre-planned Rule 10b5-1 trading plan, involved sales at weighted average prices between $45.81 and $48.06 per share. Following these trades, Collins directly holds 25,000 shares of Enliven common stock.
Trading the Move, Not the Narrative: (ELVN) Edition
This article provides an in-depth AI-generated analysis for Enliven Therapeutics Inc. (NASDAQ: ELVN), highlighting strong sentiment across all horizons and suggesting an overweight bias. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, and includes a multi-timeframe signal analysis to guide traders.
Enliven Therapeutics stock hits 52-week high at $46.83 By Investing.com
Enliven Therapeutics (ELVN) stock hit a new 52-week high of $46.83, reflecting a remarkable 194% year-to-date return, though InvestingPro data suggests it may be overvalued. The company's impressive stock performance is fueled by analyst bullishness, with price targets ranging from $39 to $60, and positive market sentiment influenced by Merck's recent acquisition of Terns Pharmaceuticals, which highlights strong demand in the oncology sector, particularly for chronic myeloid leukemia therapies.
Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market
Enliven Therapeutics Inc. (NASDAQ:ELVN) has seen its stock price surge by 194% year-to-date, fueled by growing investor interest in the chronic myeloid leukemia (CML) treatment market. This rally follows Merck's $6.7 billion acquisition of Terns Pharmaceuticals, a competitor, which strengthened Merck's oncology pipeline with TERN-701, a CML treatment in clinical trials. Enliven Therapeutics is also developing its own CML treatment, ELVN-001, currently in early-stage studies, leading investment firms Mizuho and Clear Street to maintain "outperform" ratings and "buy" recommendations for ELVN shares.
Enliven Therapeutics stock hits 52-week high at $46.83
Enliven Therapeutics (ELVN) stock hit a new 52-week high of $46.83, demonstrating a significant 194% year-to-date return, though InvestingPro indicates it may be overvalued. The company's recent performance is bolstered by Merck's acquisition of Terns Pharmaceuticals, impacting the CML market and leading to raised price targets from analysts like H.C. Wainwright and Clear Street. Despite strong investor confidence, the company has not been profitable in the past twelve months.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March
Enliven Therapeutics (NASDAQ:ELVN) experienced a 26.3% decrease in short interest in March, reducing to 6,053,456 shares, representing about 13.7% of the stock. Despite this, company insiders have been net sellers, offloading 37,460 shares worth approximately $1.04 million in the last 90 days, though insiders still own 25.9% of the company. Institutional ownership remains high at 95.08%, and the stock is trading near its 1-year high with a "Moderate Buy" consensus rating and a $43.40 price target.
Enliven Therapeutics (NASDAQ: ELVN) asks shareholders to approve charter share increase
Enliven Therapeutics (NASDAQ: ELVN) is seeking shareholder approval to increase its authorized common stock from 100 million to 200 million shares at its 2026 virtual Annual Meeting on June 9, 2026. This proposal is intended to ensure sufficient shares for future issuances, though the board currently has no plans for immediate issuance. Shareholders will also vote on the election of two Class III directors, ratification of Deloitte & Touche LLP as the independent auditor, and advisory votes on executive compensation and the frequency of future Say-on-Pay votes.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Brokerages have given Enliven Therapeutics (NASDAQ:ELVN) a "Moderate Buy" consensus rating, with an average 12-month price target of $43.40. Despite the positive analyst outlook, company insiders have been net sellers, disposing of over $1 million in stock in the last quarter. Enliven, a clinical-stage biotech, reported a quarterly EPS loss of $0.48, missing estimates, and has a market capitalization of $2.71 billion.
ELVN Earnings History & Surprises | EPS & Revenue Results | ENLIVEN THERAPEUTICS INC (NASDAQ:ELVN)
This article provides a detailed historical overview of ENLIVEN THERAPEUTICS INC (ELVN) quarterly earnings, including EPS and revenue actuals, analyst estimates, and surprise percentages. It highlights the company's past performance, upcoming earnings date, and beat rates. The data covers multiple fiscal quarters, offering insights into EPS and revenue growth trends and surprise distributions.
ELVN Surges Amid Strategic Acquisition Talks and Analyst Upgrades
Enliven Therapeutics Inc. (NASDAQ: ELVN) stock has surged by 5.89% following positive clinical trial results and increased investor interest, particularly after Merck's acquisition of Terns. Analysts anticipate further interest in ELVN from larger pharmaceutical entities due to its promising ELVN-001 compound for chronic myeloid leukemia. The company's strong financial health and strategic positioning in the biotech domain suggest a positive outlook for future growth and market interactions.
Merck’s Acquisition Sparks Surge in Enliven Therapeutics
Enliven Therapeutics Inc. (NASDAQ: ELVN) has seen an 8.96% stock surge due to promising clinical trial results and a financial firm raising its price target. Merck's acquisition of Terns has increased interest in Enliven, causing a 20% pre-market increase in its stock. The company showcases strong liquidity with a current ratio of 28.7 and no long-term debt, positioning it for potential strategic engagements and growth in the oncology paradigm.
Enliven Therapeutics Regains Attention as Stock Prices Soar
Enliven Therapeutics Inc. (NASDAQ: ELVN) is experiencing a significant stock price surge, trading up by 6.34% due to promising clinical trial results and market speculation following Merck's acquisition of Terns Pharmaceuticals. Analysts are upgrading their valuations, and while the company faces long-term profitability challenges, strong cash positions and lean operating strategies offer stability. The market is closely watching if Enliven can sustain this momentum amidst increased strategic interest from larger firms.
Enliven Therapeutics stock hits 52-week high at $40.66 By Investing.com
Enliven Therapeutics Inc. (ELVN) has reached a new 52-week high of $40.66, reflecting a 153% year-to-date surge. Despite this strong performance, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value estimate. The company maintains a "GOOD" financial health rating with more cash than debt, and has recently received positive analyst updates and increased price targets following Merck's acquisition of Terns Pharmaceuticals, highlighting interest in CML therapies.
5 Best Performing Stocks of Q1 2026 to Watch for Q2
This article lists the top 5 best-performing stocks of Q1 2026, focusing on one specific company in detail. Enliven Therapeutics, Inc. (NASDAQ: ELVN) saw a 152.25% gain, with analysts increasing price targets after a competitor acquisition and positive Phase 1b data for its ELVN-001 drug candidate for chronic myeloid leukemia. The piece also includes a speculative advertisement about an AI investment opportunity.
25,000-share resale via Jefferies — Enliven Therapeutics (NASDAQ: ELVN)
Enliven Therapeutics (NASDAQ: ELVN) submitted a Form 144 to propose the sale of 25,000 common shares through Jefferies LLC, valued at $914,750, with an entry date of March 31, 2026. The filing also detailed several past sale dispositions by Joseph Lyssikatos, a beneficial owner, including transactions in January and February 2026. A Form 144 is a notice of intent to sell restricted securities and does not guarantee the completion of the sale.
[144] Enliven Therapeutics, Inc. SEC Filing
Andrew Phillips, associated with Enliven Therapeutics, Inc. (ELVN), has filed a Form 144 to sell 26,035 shares of Common Stock acquired through a stock option exercise on March 31, 2026. This filing also discloses previous sales of 21,844 shares on February 2, 2026, and 1,520 shares on January 22, 2026. The proposed sale is valued at $1,003,610.20 and will be executed through Morgan Stanley Smith Barney LLC.
Enliven Therapeutics CMO Executes $1.2M Stock Sale | Company Update 2026 - News and Statistics
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics, recently sold 40,000 shares of the company's common stock, generating approximately $1.2 million, after exercising options. She still holds 25,000 shares directly and a considerable number of stock options. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on cancer therapies, currently conducting Phase 1 trials for two kinase inhibitor candidates, and reported a net loss over the past year.
Price-Driven Insight from (ELVN) for Rule-Based Strategy
This article provides a price-driven analysis of Enliven Therapeutics Inc. (NASDAQ: ELVN) for rule-based trading strategies, highlighting strong sentiment across all time horizons supporting an overweight bias. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated support/resistance levels.
Enliven (NASDAQ: ELVN) CMO exercises options and sells 40K shares
Helen Louise Collins, Chief Medical Officer at Enliven Therapeutics (NASDAQ: ELVN), exercised options for 40,000 shares at $2.48 each and subsequently sold all 40,000 shares at a weighted average price of $35.1006. These transactions were pre-scheduled under a Rule 10b5-1 trading plan adopted in October 2025. Following these sales, Collins directly holds 25,000 shares and maintains 136,268 equity awards.
